Back to Newsroom

Sucampo and Takeda Initiate Global Pivotal Phase 3 Program of Lubiprostone in Pediatric Functional Constipation

BETHESDA, Md. and DEERFIELD, Ill., Dec. 17, 2013 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) (“Sucampo”) and its development and commercialization partner Takeda Pharmaceuticals (“Takeda”) today announced the initiation of a global pivotal Phase 3 clinical program of lubiprostone in pediatric functional constipation. Functional constipation is a very common gastrointestinal complaint in children and is on the rise. An analysis of longitudinal data in the United States showed a nearly 4-fold increase in rates of constipation over the last decade.